Research & Development
OssDsign wins US FDA marketing clearance for Cranial PSI Accessories
14 October 2019 - Swedish medical company OssDsign AB (publ) reported on Friday the receipt of US Food and Drug Administration (FDA) 510(k) clearance (K190523) to market its Cranial PSI Accessories in...
The FDA approves new migraine treatment Reyvow
14 October 2019 - Public health agency The US Food and Drug Administration announced on Friday that it authorised the marketing of Reyvow (lasmiditan) tablets for the acute (active but short-term) tre...
Sobi announces start of tender offer for all outstanding shares of Dova Pharmaceuticals at USD27.5 per share
14 October 2019 - Swedish Orphan Biovitrum AB (Sobi)(STO:SOBI), a specialised international biopharmaceutical company transforming the lives of people with rare diseases, announced on Friday the comme...
Aerie Pharmaceuticals Names Davis as Chief Compliance Officer
11 October 2019 - - US-based ophthalmic pharmaceutical company Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has appointed Charlene E. Davis, Esq., as vice president and chief compliance officer, reporti...
Platelet BioGenesis Receives Contract Worth Up to USD 56m from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure
11 October 2019 - - US-based Platelet BioGenesis, Inc., a specialist in stem cell-derived, on-demand human platelets (PLTs+) and genetically engineered platelet-based therapeutics, was awarded a contr...
Verastem Oncology Partner Doses First Patient in Japanese Bridging Study Evaluating Copiktra in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
11 October 2019 - - US-based biopharmaceutical company Verastem, Inc. (NASDAQ: VSTM) partner Yakult Honsha Co., Ltd. (Yakult) has dosed the first patient in a Phase 1b Japanese bridging study evaluati...